q진 LCZ 수열군의 일반화된 확장 생성 방법

정정수(Jung-Soo Chung),김영식(Young-Sik Kim),장지웅(Ji-Woong Jang),노종선(Jong-Seon No),정하봉(Ha-Bong Chung) 한국통신학회 2008 韓國通信學會論文誌 Vol.33 No.11C

[1]에서 LCZ 수열군의 2배 확장을 제안하였다. 본 논문에서는 [1]에서의 2배 확장방법을 일반화하는 새로운 확장방법을 제안한다. 이 생성방법을 사용하면 인수가 (N,M,L,ε)인 q진 LCZ 수열군은 인수가(pN,pM,p「(L+1)/p」-,pε)인 q진 LCZ 수열군이 된다. 이 때, p는 소수이고 p는 q의 약수다. 특히 L≡p-1modp 일 때, 확장된 q진 LCZ 수열군의 인수는 (pN,pM,L,pε)이 된다. In this paper, a new extending method of q-ary low correlation zone(LCZ) sequence sets is proposed, which is a generalization of binary LCZ sequence set by Kim, Jang, No, and Chung. Using this method, q-ary LCZ sequence set with parameters (N,M,L,ε) is extended as a q-ary LCZ sequence set with parameters (pN,pM,p「(L+1)/p」-1,pε), where p is prime and p|q.

혈액투석 환자에게서 발생한 재생불량성 빈혈 1예

정지용,윤나라,강대웅,오종찬,장재현,선길홍,박경희,정종훈,김현리 朝鮮大學校 附設 醫學硏究所 2005 The Medical Journal of Chosun University Vol.30 No.1

Aplastic anemia is a disease characterized by pancytopenia in the peripheral blood and hypocellular bone marrow with the fatty infiltration. The causes of the acquired aplastic anemia were usually related to drugs and immune-related diseases. A 34-years old man was admitted due to general weakness. He has been going hemodialysis for 2 years because of end stage renal disease (ESRD) due to chronic glomerulonephritis. At admission, laboratory tests showed hemoglobin 6.2 g/dL, hematocrit 18.0 %, WBC 5,710mm (neutrophil 71.8%, lymphocyte 19.1%, monocyte 5.9%), reticulocyte 1.9%, platelet 93,000/mm, Fe 12.8 ug/dL, TIBC 204 ug/dL, ferritin 941.47 ng /ml, haptoglobin 0.72 g/L, vitamin B12 508.17 pmol/L, folate 24 ng/mL, total protein 6.54 g/dL, albumin 3.76 g/dL, Alk. pohsphatase 79 IU/L, AST 30.0 IU/L, ALT 39.7 IU/L, total bilirubin 0.57 mg/dl, BUN 79.4 mg/dl and creatinine 10.18 mg/dl. Peripheral blood smear showed the normocytic normochromic anemia with anisocytosis. Anemia was diagnosed but it was irresponsive to the recombinant human erythropoietin (EPO) and blood transfusion. In the bone marrow aspiration smear were there the hypoplastic myeloid and erythroid precursors. The bone marrow biopsy section showed the hypoplasia of all components (10-20%) and the fatty infiltration. We have experienced one case of the idiopathic aplastic anemia in a patient going through hemodialysis and we just report it with documentary records. 저자들은 혈액 투석 중인 환자에서 약물, 면역계 이상등의 원인을 발견할 수 없었음에도 재생 불량성 빈혈이 발생한 1예를 경험하여 문헌 고찰과 함께 보고하는 바이다.

말기신부전 환자에서 혈액투석 전후의 QT간격분산 비교

강대웅,정지용,윤나라,안치용,김종오,신병철,정종훈,김현리 朝鮮大學校 附設 醫學硏究所 2006 The Medical Journal of Chosun University Vol.31 No.2

Background: Some cases of QT interval, corrected QT interval (QTc), QT dispersion (QTd) and corrected QT dispersion (QTcd) have been reported in ESRD, but these results are variable and the influence of a hemodialysis is still controversial, In this study, we investigated the effect of hemodialysis on QT and QTc interval and QT and QTc dispersion in patients with ESRD 15 min before and 15 minute after each hemodialysis. Methods: Sixty-seven patients with ESRD (men 33 & women 34) on three-times stable hemodialysis (>3 months) were randomly enrolled. Fifty control subjects with a similar age and normal renal function were enrolled from this hospital. Routine biochemical studies were measured pre- and post dialysis, at the time of the ECG. Plasma Na+, K+, BUN, creatinine, ionized calcium and phosphate were checked. Twelve-lead electrocardiographs were performed at 10㎜/mv and 50㎜/s using a HewIett-Packard Pagewriter 100, before and after a single hemodialysis session.The QT interval was measured from the onset of the QRS complex to the end of the T wave. If the end of the T wave was not clear in a particular lead then it was excluded from analysis. When U waves were present, the end of the T wave was taken as the nadir between the T and U waves. Each QT interval was corrected for heart rate using Bazett's formula (QTc==QT/√(RR)) (ms). The difference between maximal and minimal QT interval duration was defined as QT dispersion (QTd) in each of the 12 leads. Result: This study demonstrates that QT, QTd, QTcd is higher in hemodialysis patients compared with control subjects, and QT and QTd rise postdialysis to levels comparable to those seen acutely following myocardial infarction, when patients are at greatly increased risk of potentially fatal ventricular arrhythmias, Conclusions: QT interval and QT dispersion, markers of risk for arrhythmias and sudden death, are elevated in hemodialysis patients, and rise postdialysis. QT interval and QT dispersion is an easily obtainable, noninvasive, simple, inexpensive, and widely available method of risk stratification in uremic patients receiving chronic dialysis. Additional studies are needed to clarity whether increased postdialysis QT dispersion results in an increased occurrence of arrhythmias.

전이성 신세포암 환자에서의 IFN-α와 5-FU를 이용한 복합 면역 화학 요법

김세웅,이지열,장광식,박왕진,정호석,조용현,윤문수 대한화학요법학회 2000 대한화학요법학회지 Vol.18 No.3

목적 : 전이성 신세포암의 경우 일반적으로 항암 화학요법, 방사선 치료 그리고 호르몬 치료 등의 다양한 치료 방법에도 불구하고 그 치료 성적이 불량하며 최근 진행된 전이성 신세포암이 치료에 사용되고 있는 면역요법과 면역화학요법의 치료 효과에 대한 많은 논란이 있다. 이에 저자들은 전이성 신세포암 환자들을 대상으로 시행한 interferon-α와 5-fluorouracil의 병용투여에 대한 면역화학요법의 치료 성적, 추적관찰 결과 및 부작용의 발현정도를 확인하여 그 임상적 유용성을 알아보고자 하였다. 방법 : 1995년 3월부터 2000년 2월까지 가톨릭 대학 부속 성모 병원에서 치료를 받았던 진행성, 전이성 신세포암 환자들 중 interferon-α와 5-fluorourcail의 복합면역화학요법을 시행 받고 추적관찰이 가능했던 총 17명의 환자를 대상으로 하였다. 대상 환자들에 대해 28일을 주기로 5-fluorouracil 750㎎/㎡(Body surface area)을 5일간 지속성 정맥 주사로 투여한 후 주 3회 interferon-α 300만 unit를 4주간 피하 주사하였다. 이들에 대해 8주마다 전산화 단층촬영, 동위원소 골주사, 흉부단순 촬영 등의 영상 진단을 통한 정기적인 추적 관찰을 시행하고 이들의 치료 성적, 추적관찰 결과 및 부작용 등에 대해 알아보았다. 결과 : Interferon-α와 5-Fluorouracil의 복합면역화학요법을 이용한 전체 17명의 전이성 신세포 암 환자의 경우 반응율은 완전관해는 없었으나 부분관해를 보인 경우가 2명(11.8%), 안정상태 유지는 6명(35.3%)이었다. 폐전이의 경우 복합면역화학요법에 대해 비교적 좋은 반응을 기대할 수 있었으며 이들의 생존 기간의 중앙값은 13.8개월이었다. 거의 모든 환자에서 미열을 동반한 전신 증상과 전신 쇠약감을 관찰 할 수 있었고 그 밖에 오심, 구토 및 설사 등의 소화기 증상과 두통 등의 경미한 부작용을 일부 환자에서 관찰할 수 있었으나 백혈구 감소증, 혈소판 감소증과 간기능 이상 등의 심각한 부작용을 보인 경우는 극히 적었다. 결론 : 전이성 신세포암은 비교적 그 예후가 불량하며 동시에 효과적인 치료 방법이 명확히 알려지지 않은 상태이다. 이러한 전이성 신세포암의 치료에 대한 interferon-α와 5-fluorouracil의 복합면역화학요법은 다른 종양의 치료에 비해 비교적 낮은 반응률과 고비용이 문제점으로 생각되나 비교적 부작용이 적은 안전한 치료 방법이므로 전이상 신세포암 환자에 있어 시행해 볼 가치가 있는 치료 방법의 하나로 사료된다. Background : Renal cell carcinoma is relatively resistant to both chemotherapy and immunotherapy. In this study, we evaluated and verified the efficacy and toxicity of therapies using interferon-α plus 5-fluorouracil in patients with metastatic renal cell carcinoma. Methods : A total of 17 patients with metastatic renal cell carcinoma were treated with interferon-α (3 million units/day. 3 times/week) subcutaneously plus 5-fluorouracil (750㎎/㎡ /day for 5 days) intravenously every 28 days from March 1995 to February 2000. We studied the response rate and the side effects of this regimen. Results : Among 17 patients treated with interferon-a plus 5-fluorouracil, 2 patient with lung metastasis was achieved partial remission (11.8%) and 3 patient with lymph node metastasis, 2 patients with lung metastasis and I patient with lung and bone metastases were achieved stable disease (35.3%). I and 5 year survival rates and median survival duration were 55%, 7% and 13.8 months, respectively. There were only mild to moderate side effects. The most common side effects were flu-like symptom such as fever, chill and malaise followed by gastrointestinal symptom such as nausea, vomiting and diarrhea, headache. High grade toxicities such as severe neutropenia and thrombocytopenia were rare. Conclusion : Immunochemotherapy using interferon-α plus 5-fluorouracil were moderately effective with modest toxicity in metastatic renal cell carcinoma. The most favorable response can be expected in lung metastasis. Most of side effects were tolerable. The effective therapy in patients with metastatic renal cell carcinoma should be studied and evaluated by further large randomized trials.

혈액투석중인 말기신부전 환자에서 Fludrocortisone acetate (FCA) 투여 후 혈청 칼륨 저하 효과

류봉관,강대웅,정지용,윤나라,신병철,박경희,정종훈,김현리 朝鮮大學校 附設 醫學硏究所 2005 The Medical Journal of Chosun University Vol.30 No.1

Background: Hyperkalemia is a commonly encountered problem in dialysis patients with end-stage renal disease. In this study we evaluated the effect of mineralocorticoid therapy (fludrocortisono acetate) on serum potassium level in the serum of hyperkalemic end-stage renal disease patients. Methods: Fourteen patients on hemodialysis receiving fludrocortisone acetate (FCA) 0.1 mg/day were observed for 2 months periods. Consecutive monthly biochemical profiles were compared for the druration of the pre-and post-treatment of FCA. Result: Fourteen patients with mean age (±SE) of 51.5 years (4 males and 10 females) and mean hemodialysis period of 51.9 months were studied. Mean serum potassium levels significantly fell (p<0.05) during the post-FCA period (5.2±0.66 mEq/L) compared with potassium levels during the pre-FCA (5.8±0.43 mEq/L) period. Pre-and post-FCA values were not different for sodium, chloride, protein, albumin, AST/ALT, glucose, blood nitrogen, creatinine, phosphate and calcium. Conclusions: FCA appears to decrease serum potassium value in patients with end-stage renal disease. These results suggested that FCA could be effective to treat hyperkalemia without any adverse effect in patients undergoing hemodialysis.

국산 Avana 인공치아와 외국산 ITI 인공치아의 악골조직내 적합성에 관한 비교연구

유재하,이지웅,백성흠,정원균,김종배 大韓顎顔面成形再建外科學會 2002 Maxillofacial Plastic Reconstructive Surgery Vol.24 No.6

The purpose of this article is to confirm the longterm biocompatibility of national Avana implant and international ITI implant in dogs. At the fourth month after extreaction of the mandibular third and fourth premolar in three dog, both implants were inserted using careful atraumatic technique and prosthetic abutments were applied onto the implants in three months. After that, the implants were examined by naked eye and radiographic image every three months during 1 year, for detection of the complications, such as, mobility, bone resorption and wound infection. At 1 year after application of prosthetic abutment, the dogs were sacrificed for the histopathologic analysis by light microscope. The results obtained were as follows; 1. All implants had the ralatively good prognosis without mobility, wound infection and moderate bone resoprtion, in clinical and radiological evaluation during one year. 2. The all histopathologic specimens at one year after application of prosthetic abutment onto the implants showed the distinct osseointegration between implant system and bone, with projection of new bone apposition onto the peri-implant tissue. But Avana implants had the less osseointegration than ITI implants in the cancellous and marrow layer of jaw bone. 3. The all histopathologic specimens at one year after application of prosthetic device showed the firm junction by dense connective tissue pattern between the implant and the gingival portion. But Avana implants had the less firmer junction than ITI implants. 4. The authors confirmed that Avana implant and ITI implant have more higher tissue biocompatibility in dental implantation, but ITI implant has the more osseointegration than the Avana implant.

호르몬 불응성 전립선암 환자에서 mitoxantrone과 prednisone의 병합화학요법 후 통증완화 및 삶의 질 측정

이홍우,이지열,김세웅,이충범,강성학,조용현,황태곤,박용현,윤문수 대한화학요법학회 2000 대한화학요법학회지 Vol.18 No.3

목적 : 호르몬 불응성 전립선암 환자의 생명을 연장시키는 치료법은 현재로는 없으며, 현 시점에서의 치료목표는 증상의 경감 및 소실에 따른 삶의 질 향상에 두고 있다. 호르몬 불응성 전립선암의 고식적인 치료에 일차적인 치료법으로 간주되는 mitoxantrone과 prednisone의 화학요법이 호르몬 불응성 전립선암 환자의 통증완화 및 삶의 질에 어떠한 영향을 미치는지 알아보았다. 방법 : 1998년 7월부터 1999년 12월까지 증상이 있는 18명의 호르몬 불응성 전립선암 환자를 대상으로 하였으며, 일차적인 치료의 목표는 환자 본인이 기록하는 McGill-Melzack 6단계 통증척도에서 진통제의 증량 없이 2점이 감소(또는 첫 점수가 1점일 경우 통증의 완전소실)하는 것으로 하였다. 이러한 기준은 최소 3주 간격으로 시행한 자가 기록조사에서 연속적으로 2번 이상 유지될 때 유효한 것으로 간주하였다. 건강과 관련된 삶의 질 측정은 전신적 치료의 임상적 응용을 위한 실제적인 측정방법으로 개발되어 환자가 직접 작성하는 전립선암 특이성 삶의 질 측정기구(Prostate Cancer-Specific Quality-of-Life Instrument : PROSQOLI)의 비례연속형의 자가측정 척도(linear analogue self-assessment scale : LASA)를 이용하였으며, ECOG performance status를 사용하여 전신상태의 변화도 측정하였다. 결과 : 통증의 경감으로 나타나는 고식적인 치료의 반응은 66.7%(12/18)에서 나타났으며, 반응의 지속기간은 2개월에서 10개월까지로 평균 4.2±3.6개월이었다. PROSQOLI로 측정한 삶의 질은 통증에 대한 고식적인 치료반응을 보인 12명(66.7%) 모두가 삶의 질이 개선되었으며 특히 통증, 변비, 소변보기, 전반적인 복지상태에서의 유의한(p<0.05) 증가를 보였다. 치료 후 혈장 PSA 수치는 고식적인 반응의 유무에 관계없이 별 다른 변화를 보이지 않았으며, 골주사 또는 전산화 단층촬영으로 측정한 방사선학적 병변은 고식적인 반응을 보인 2명을 제외하고 치료 전과 비교하여 차이를 보이지 않았다. 병합 화학요법과 관련된 특별한 부작용은 관찰되지 않았다. 결론 : 통증을 동반한 호르몬 불응성 전립선암에서 mitoxantrone과 prednisone의 병합화학요법은 66.7%의 환자에서 통증의 감소 및 삶의 질이 향상되었다. 현재는 혈장 PSA 수치, 병소의 크기나 개수등이 치료의 지침이나 치료결과의 판정을 위한 객관적인 기준으로 사용되는 경향이 있지만, 앞으로는 환자를 중심으로 통증을 포함한 삶의 질 측정이 고식적 치료 후 치료결과 판정에 있어 객관적이고 적절한 방법이 될 것이다. Background : There is no evidence that therapeutic modalities prolong the survival of patients with hormone-refractory prostate cancer nowadays. The main goal of treatment is therefore improvement in quality-of-life including palliation of symptoms. We performed this study to investigate the benefit of mitoxantrone and prednisone chemotherapy in patients with symptomatic hormone-refractory prostate cancer using relevant end points of palliation regarding to pain and quality-of-life. Methods : From July 1998 to December 1999, we assessed the 18 patients with symptomatic hormone-refractory prostate cancer receiving mitoxantrone and low dose prednisone. The treatment end point was a palliative response defined as a 2-point decrease in pain assessed by a 6-point pain scale complemented by patients (or complete loss of pain if initially 1+) without an increase in analgesic medication and maintained for two consecutive evaluations at least 3 weeks apart. Health-related quality-of-life was evaluated with a series of linear analogue self-assessment(LASA) scale of the Prostate Cancer-Specific Quality-of-Life Instrument (PROSQOLI) and performance status was also measured. Results : Palliative responses were observed in 12(66.7%) of 18 patients. The duration of palliative responses were 4.2±3.6 months(range: 2 to 10 months). Treatment was well tolerated without specific side effects. There were no differences in prostate-specific antigen (PSA) level following treatment and no significant changes of radiologic findings evaluated by bone scan and/or CT were noted except 2 cases after chemotherapy. All the responding patients had an improvement in quality-of-life scales and performance status, however serum PSA levels were not changed. Conclusions : Chemotherapy with mitoxantrone and prednisone provides palliation and an improvement in quality-of-life for more than half (66.7%) of the patients with symptomatic hormone-refractory prostate cancer.

유지 투석중인 만성 신부전환자에서 허혈성 심질환의진단 지표로서의 심장트로닌-I의 유용성

신병철,강대웅,정지용,류봉관,서영욱,김정인,김범윤,김현리,정종훈 朝鮮大學校 附設 醫學硏究所 2004 The Medical Journal of Chosun University Vol.29 No.1

Background : Coronary disease is highly prevalent in patient with end stage renal disease (ESRD) and account for much of their observed morbidity and mortality. Troponin-I consistently maintains a high sensitivity and specificity and is most sensitive marker for ischemic heart disease (IHD). Method : We examed 49 hernodialyzed patients (22 male, 27 female) without evidence of acute coronary syndrome (ACS) for 6 months. Biochemical markers were measured in serial predialysis blood samples. For analysis, we used two cardio-specific assays for troponin-T (cTnT) as well as for troponin-I (cTnI) and compared the results with CK-MB (reference value ≤ 4.0 ng/mL) concentration. Results : Myocardial ischemia was observed in 47% (23/49) of patients. cTnT level above 0.1 ng/mL. and cTnI level above 0.5 ng/mL, were observed in 22% (11/49) and 20% (10/49) of patients respectively. cTnI revealed significantly higher positive rate in patients with myocardial ischemia than the patients without myocardial ischemia (43 % vs 30%) (p<0.05). cTnT and CK-MB revealed no difference in positive rate between the patients with and without myocardial ischemia (cTnT : 30% vs 15% and CK-MB : 30% vs 19%). The sensitivity and specificity of cTnI to myocardial ischemia were higher than those of cTnT and CK-MB (sensitivity 43% vs 30% and 30%. specificity 100% vs 85% and 81%). Conclusion: Both cTnT and cTnI are useful in ruling out myocardial injury in chronic renal failure patients. But. cTnI is a more sensitivity and excellent specificity of ischemic heart disease than cTnT and CK-MB in hemodialyzed patients. In patients with ischemic heart disease, the presences of DM and advanced age were higher than those in patients without ischemic heart disease (p<0.05). Among the baseline characteristics old age, elevated LDH and diabeties were significant more frequent in the patients with elevation of cardiac troponin-I (p>0.5 ng/mL) than those with cardiac troponin-I (p<0.5 ng/mL), p=0.038, p=0.049, and p=0.045, respectively. Our results suggest that these cTnI is the potential diagnostic marker for the prediction of IHD in ESRD patients.

심인성 색전 요인이 없는 뇌경색 환자에서 경식도 심초음파와 Acoustic Quantification을 이용한 대동맥 탄성의 평가

이종민,윤호중,임효영,박지원,김휘열,전희경,문건웅,정욱성,채장성,김재형,최규보,홍순조 대한순환기학회 2000 Korean Circulation Journal Vol.30 No.8

심전도에서 조기재분극을 보인 특발성 심실세동

이정은,함효주,이관용,노지웅,유진석,정우백 이화여자대학교 의과학연구소 2014 EMJ (Ewha medical journal) Vol.37 No.2

Early repolarization is a common electrocardiographic (ECG) feature found in young adults, men and athletes, and has been considered to be a benign feature for the last several decades. But recent studies suggest that early repolarization may be related to idiopathic ventricular fibrillation and sudden cardiac death. We report a young man, 35 years old, who had life threatening ventricular fibrillation and sudden cardiac arrest. He was evaluated for cardiac causes of ventricular fibrillation. There was no explanation other than that his ECG showed an early repolarization pattern so we treated him with implantable cardioverter defibrillator. Thus, we suggest that early repolarization may be related with life threatening ventricular arrhythmia.